Berlin Conference: Novel Antimicrobials & AMR Diagnostics
3Small and medium-sized enterprises (SMEs) constitute the major innovation engine in the AMR arena with the most significant pipelines of novel antimicrobials and diagnostics targeting multidrug-resistant bacteria. Although European biotech companies with AMR activities raised more than €220m this year, sustainable business models and market prospects are still challenging.
At the same time, a series of global initiatives were started: the Interagency Consultative Group (IACG) established by the United Nations; the Global R&D Hub resulting from the 2017 G20 summit; international multimillion-euro funding bodies such as CARB-X and the Global Antibiotic Research and Development Partnership (GARDP); the AMR Call to Action initiative, and the InnoFin Infectious Disease program financed by the European Investment Bank. These initiatives are particularly welcomed by SMEs; however, they call for implementing further supportive instruments.
More than 40 speakers & 200 participants expected
Berlin-based BIOCOM AG together with the European SME association BEAM alliance invite key players to the Berlin Conference “Novel Antimicrobials & AMR Diagnostics” in March 2018. The conference will provide a discussion platform to address the specific challenges faced by SMEs with more than 40 speakers representing all facets of the industry: companies (Janssen Diagnostics, Basilea, Polyphor, BioVersys, Curetis, MeMed, GFC Diagnostics); start-ups (AGIleBiotics, PhagoMed, Oppilotech, Vaxdyn, SPINDIAG); funding bodies (CARB-X, GARDP, Find Diagnostics); investors (Forbion Capital, European Investment Bank); and several academic experts from the AMR centre, the Universities of Antwerp and Edinburgh, the University of Uppsala and Institut Pasteur.
The afternoon will feature pitching opportunities for investors, funders and start-ups. Posters from the German research associations Fraunhofer, Helmholtz and Leibniz as well as the Netherlands Antibiotic Development Partnership will highlight promising R&D projects within an exhibition area throughout the day. The event is further supported by the EU-funded European Gram Negative Anti-Bacterial Engine (ENABLE) consortium, Boehmert & Boehmert, and the British Department of International Trade. The organizers expect more than 200 participants from industry, science and policy.
More information: www.berlin-conferences.com